‘Travesty of justice’: Cop29’s controversial deal

Loading player...
Madeleine Finlay hears from the Guardian’s environment editor, Damian Carrington, about the controversial climate finance deal that brought Cop29 negotiations to a close in the early hours on Sunday morning in Baku, Azerbaijan. Developing countries asked rich countries to provide them with $1.3tn a year to help them decarbonise their economies and cope with the effects of the climate crisis. But the final deal set a pledge of just $300bn annually, with $1.3tn only a target. Damian tells Madeleine how negotiations unfolded, and what we can expect from next year’s conference in Brazil. Help support our independent journalism at theguardian.com/sciencepod
25 Nov 2024 English United Kingdom Science · Nature

Other recent episodes

Streams of medicines: how Switzerland cleaned up its act

Switzerland is leading the world in purifying its water of micropollutants, a concoction of chemicals often found in bodies of water that look crystal clear. They include common medicines like antidepressants and antihistamines, but have unknown and potentially damaging consequences for human and ecosystem health. In the second of a…
10 Apr 17 min

Streams of medicines: what’s hiding in the UK’s waterways?

The UK is known for its national parks: areas of outstanding natural beauty with rolling hills and crystal-clear streams and lakes. But research has shown that England’s most protected rivers are full of pharmaceuticals. In episode one of a two-part series, biodiversity reporter Phoebe Weston tells Madeleine Finlay about the…
8 Apr 17 min

Keto: what’s the science behind the diet?

While other diet fads come and go, the ultra low carbohydrate Keto diet seems to endure. But as scientists begin to understand how the diet works, more is also being discovered about its risks. To find out more, Madeleine Finlay speaks to Javier Gonzalez, professor in the department of health…
1 Apr 17 min

The rise and fall of DNA testing company 23andMe

The genetic testing firm 23andMe has filed for bankruptcy, another twist in the story of a company that promised a pioneering approach to precision health. Now users are scrambling to delete their personal data, with the future ownership of the firm uncertain. To understand the highs and lows of 23andMe’s…
27 Mar 21 min